MedTrace Logo

Optimal Number of Hyperbaric Oxygen Treatments for Carbon Monoxide Poisoning

NCT06619717 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-03-13

No results posted yet for this study

Summary

The optimal treatment strategy with hyperbaric oxygen therapy has been the subject of some debate over the past 3 decades. Initial landmark studies showed a decrease in the incidence of DNS with a single treatment and also with three treatments over the course of 24 hours. These two strategies have continued to be used widely without further evidence comparing them in a direct fashion. Retrospective publications in the years since have been largely conflicting about the benefit of additional hyperbaric treatments. The investigators would seek to randomize patients with carbon monoxide poisoning to receive with 1 or 3 treatments with hyperbaric oxygen and measure their neurologic outcomes.

Conditions

  • Hyperbaric Oxygen Therapy
  • Carbon Monoxide Poisoning

Interventions

PROCEDURE

Hyperbaric Oxygen Therapy

Three treatments with hyperbaric oxygen therapy. The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be: Weaver protocol, or similar (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. Repeat this every 8 hours until 3 treatments are complete.)

PROCEDURE

Hyperbaric Oxygen Therapy

Single treatment with hyperbaric oxygen. Exact parameters left to treating physician but commonly: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Brian Rowe, MD, MSc, CCFP (EM), FCCP · Professor in the Department of Emergency Medicine, Faculty of Medicine & Dentistry, College of Health Sciences, at the University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-24
Primary Completion
2026-02-10
Completion
2026-02-10

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06619717 on ClinicalTrials.gov